ATLANTA, GA – – (Businesswire – August 28, 2017) – – Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE: TEVA) American Depositary Shares (“ADSs”) on the New York Stock Exchange and/or common stock on the Tel Aviv Stock Exchange (“TASE”) between November 15, 2016 and August 2, 2017. The complaint alleges Teva issued false and misleading statements during that time. Specifically, the Complaint alleges Teva failed to disclose the poor performance of its U.S. generics business and the subsequent goodwill impairment charge stemming from the Company’s purchase of Actavis Generics. On August 3, 2017, Teva announced a $6.1 million goodwill impairment charge in the second quarter of 2016. The price of Teva common stock has declined following the report. If you purchased Teva shares between November 15, 2016 and August 2, 2017 and suffered losses on that investment, you are encouraged to visit the firm’s website at www.holzerlaw.com to receive additional information about your legal rights. You can also contact Corey D. Holzer, Esq. at email@example.com or Alexandria P. Rankin, Esq. at firstname.lastname@example.org, or call the firm by toll-free telephone at (888) 508-6832 for more information. The case is pending in the United States District Court for the Eastern District of Pennsylvania and the deadline to move for appointment as lead plaintiff is October 23, 2017.